L&G Pharma Breakthrough UCITS ETF ISIN IE00BF0H7608, WKN A2H9XR

 
Add to portfolio Watch Compare
 
 
 
 

Current quote and strategy of L&G Pharma Breakthrough UCITS ETF

Quote
EUR 10.56
Last quote
21.01.22
10.12 52 weeks low/high 11.75
52 weeks low/high
 
Investment strategy

The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.

 

Solactive Pharma Breakthrough Value (1)

Equity (1185) World (286) Health Care (12)
 

Risk and fees of L&G Pharma Breakthrough UCITS ETF

Risk
EUR 28 m
Fund size
Fund size category

Replication

Physical (Full replication)
Legal structure ETF
Strategy risk Long-only
Fund currency USD

Currency risk

Currency unhedged
Volatility 1 year (in EUR) 15.01% Risk category
Inception/ Listing Date 23 January 2018
Fees
0.49% p.a.
Total expense ratio
0.04% Compare 1.38%
Compare ( Equity )
Dividend/ Taxes
Distribution policy Accumulating
Distribution frequency -
Fund domicile Ireland
Tax data Bundesanzeiger
Legal structure
Fund Structure Open-ended Investment Company (OEIC)
UCITS compliance Yes
Fund Provider Legal & General (LGIM)
Administrator BNY Mellon Fund Services (Ireland) Designated Activity Company
Investment Advisor Legal & General Investment Management Limited
Custodian Bank BNY Mellon Trust Company (Ireland) Limited
Revision Company EY
Fiscal Year End 30 June
Swiss representative State Street Bank International GmbH, München, Zweigniederlassung Zürich
Swiss paying agent State Street Bank International GmbH, München, Zweigniederlassung Zürich
Tax Status
Germany 30% tax rebate
Switzerland No ESTV Reporting
Austria Tax Reporting Fund
UK UK Reporting
Replication, swap, securities lending
Indextype Total return index
Swap counterparty -
Collateral manager BNY Mellon Fund Services (Ireland) Limited
Securities lending No
Securities lending counterparty
 
 
 

Performance of L&G Pharma Breakthrough UCITS ETF

Loading...
 
 

Exposure

Below you find information about the composition of the L&G Pharma Breakthrough UCITS ETF.

Top 10 Holdings
Weight of top 10 holdings
out of 31
38.65%
ENDO INTERNATIONAL PLC
6.99%
SUPERNUS PHARMACEUTICALS ORD
3.84%
XENCOR INC/D
3.69%
ABBVIE ORD SHS
3.64%
CSL ORD
3.53%
SAREPTA THERAPEUTICS INC DE
3.48%
ROCHE ORD
3.42%
SANOFI-AVENTIS ORD
3.39%
SWEDISH ORPHAN BIOVITRUM ORD
3.37%
BIOMARIN PHARMACEUTICAL ORD
3.30%
Countries
United States
51.47%
Japan
9.46%
Ireland
6.99%
Switzerland
6.62%
Other
25.46%
Show more
Sectors
Health Care
99.94%
As of 29/10/2021
 
 

Description of L&G Pharma Breakthrough UCITS ETF

The L&G Pharma Breakthrough UCITS ETF invests in stocks with focus Health Care, World. The dividends in the fund are reinvested (accumulating).

The total expense ratio amounts to 0.49% p.a.. The fund replicates the performance of the underlying index by buying all the index constituents (full replication). The L&G Pharma Breakthrough UCITS ETF is a small ETF with 28m Euro assets under management. The ETF is older than 3 years and is domiciled in Ireland.
 

Look for similar ETFs

 
 

Returns of L&G Pharma Breakthrough UCITS ETF

Returns in years
Loading...
Returns in periods
Loading...
 
Monthly returns in a heat map
Loading...
 
 

Listings of L&G Pharma Breakthrough UCITS ETF

Loading...
 
Rolling 1 year volatility

Analyse the 1 year volatility over time.

Learn more
 

Take advantage of all comfort features and portfolio comparisons with justETF Premium. The Premium version includes features like simulation of ETF portfolios, details analysis, monitoring, rebalancing and more.

Upgrade now

Track your ETF strategies online

 
— Data provided by Trackinsight, etfinfo, Xignite Inc. and justETF GmbH.

All quotes are 15 minutes delayed stock exchange quotes or NAVs (=daily published by fund provider). Returns include dividend payments. There is no warranty for completeness, accuracy and correctness for the displayed information.